A Long-Term Prospective Observational Safety Study of the Incidence of and Risk Factors for Fibrosing Colonopathy in US Patients With Cystic Fibrosis Treated With Pancreatic Enzyme Replacement Therapy: A Harmonized Protocol Across Sponsors(The CF-FC Study)
Phase of Trial: Phase IV
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Pancrelipase (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions
- Sponsors Abbott Laboratories; AbbVie
- 30 Aug 2017 Planned End Date changed from 31 Jul 2022 to 29 Jul 2022.
- 30 Aug 2017 Planned primary completion date changed from 31 Jul 2022 to 29 Jul 2022.
- 23 Apr 2015 New trial record